Up till now, no treatment options are available for prevention of PIPN. Several options have been investigated for treatment of CIPN with only duloxetine had proven benefits. Additional investigations are needed to develop preventive and ameliorative therapy of PIPN.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Adult patients (\>18 years old).
Patients with confirmed diagnosis of non-metastatic breast cancer planned to receive weekly adjuvant/neo-adjuvant paclitaxel.
Patients with Eastern Cooperative Oncology Group (ECOG) performance (Oken et al., 1982) status of 0-2.
You may not be if
Patients with pre-existing neuropathic conditions.
Patients with diabetes mellitus.
Patients with a history of seizure disorder.
Patients with renal impairment (creatinine clearance less than 60 ml/min), or hepatic impairment (defined as ALT an AST \> 3 times upper limits of normal)
Patients with inadequate bone marrow functions (defined as absolute neutrophilic count less than 1,500/mm3 or platelets count less than 100,000/mm3).
Concomitant use of vitamin B1, B6, B9, or B12.
Patients receiving medications that possibly induce peripheral neuropathy including amiodarone, colchicine, metronidazole, antimycobacterials, and nucleoside reverse transcriptase inhibitors, and phenytoin (Jones et al., 2020).
Patients receiving gabapentinoids, antidepressants, or opioids.
Pregnancy or lactation.
History of hypersensitivity to memantine.
Clareo Health | "The Effect of Memantine on the Prevention and Amelioration of Paclitaxel-induced Toxicity in Breast Cancer Patients"
